This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 44/3/264    most recent 01.HYP.0000138688.78906.6bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhao, Q. Articles by Egashira, K. Search for Related Content PubMed PubMed Citation Articles by Zhao, Q. Articles by Egashira, K. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Vasculitis Related Collections Remodeling Other arteriosclerosis Growth factors/cytokines Valvular heart disease Gene therapy Mechanism of atherosclerosis/growth factors

(Hypertension. 2004;44:264.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Essential Role of Vascular Endothelial Growth Factor in Angiotensin II–Induced Vascular Inflammation and Remodeling

Qingwei Zhao; Minako Ishibashi; Ken-ichi Hiasa; Chunyan Tan; Akira Takeshita; Kensuke Egashira

From the Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Correspondence to Kensuke Egashira, MD, PhD, Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail egashira{at}cardiol.med.kyushu-u.ac.jp

Angiotensin II (Ang II) upregulates vascular endothelial growth factor (VEGF) and activates vascular inflammation. However, the decisive role of VEGF in Ang II–induced vascular inflammation and remodeling has not been addressed. Ang II infusion to wild-type mice increased local expression of VEGF and its receptors in cells of aortic wall and plasma VEGF, and caused aortic inflammation (monocyte infiltration) and remodeling (wall thickening and fibrosis). Hypoxia-inducible factor-1 colocalized with VEGF-positive cell types. Blockade of VEGF by the soluble VEGF receptor 1 (sFlt-1) gene transfer attenuated the Ang II–induced inflammation and remodeling. The sFlt-1 gene transfer also inhibited the increased expression of VEGF and inflammatory factors such as monocyte chemoattractant protein-1. In contrast, sFlt-1 gene transfer did not affect Ang II–induced arterial hypertension and cardiac hypertrophy. VEGF is an essential mediator in Ang II–induced vascular inflammation and structural changes through its proinflammatory actions.

Key Words: growth substances • arteriosclerosis • remodeling • angiotensin II • endothelial growth factors

This article has been cited by other articles:

				J.-i. Koga, T. Matoba, K. Egashira, M. Kubo, M. Miyagawa, E. Iwata, K. Sueishi, M. Shibuya, and K. Sunagawa Soluble Flt-1 Gene Transfer Ameliorates Neointima Formation After Wire Injury in flt-1 Tyrosine Kinase-Deficient Mice Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 458 - 464. [Abstract] [Full Text] [PDF]

				Q. Hao, L. Wang, and H. Tang Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells Am J Physiol Cell Physiol, April 1, 2009; 296(4): C821 - C827. [Abstract] [Full Text] [PDF]

				M. C. John, R. Wessely, A. Kastrati, A. Schomig, M. Joner, M. Uchihashi, J. Crimins, S. Lajoie, F. D. Kolodgie, H. K. Gold, et al. Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 535 - 544. [Abstract] [Full Text] [PDF]

				M. Joner, G. Nakazawa, A. V. Finn, S. C. Quee, L. Coleman, E. Acampado, P. S. Wilson, K. Skorija, Q. Cheng, X. Xu, et al. Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents J. Am. Coll. Cardiol., July 29, 2008; 52(5): 333 - 342. [Abstract] [Full Text] [PDF]

				L. I. Schrader, D. A. Kinzenbaw, A. W. Johnson, F. M. Faraci, and S. P. Didion IL-6 Deficiency Protects Against Angiotensin II Induced Endothelial Dysfunction and Hypertrophy Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2576 - 2581. [Abstract] [Full Text] [PDF]

				T. Nakagawa Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1665 - F1672. [Abstract] [Full Text] [PDF]

				S. Anwaruddin, A. T. Askari, and E. J. Topol Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine J. Am. Coll. Cardiol., January 23, 2007; 49(3): 279 - 289. [Abstract] [Full Text] [PDF]

				D. A. Long, W. Mu, K. L. Price, C. Roncal, G. F. Schreiner, A. S. Woolf, and R. J. Johnson Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension Am J Physiol Renal Physiol, December 1, 2006; 291(6): F1248 - F1254. [Abstract] [Full Text] [PDF]

				R. Wang, R. Shamloul, X. Wang, Q. Meng, and L. Wu Sustained Normalization of High Blood Pressure in Spontaneously Hypertensive Rats by Implanted Hemin Pump Hypertension, October 1, 2006; 48(4): 685 - 692. [Abstract] [Full Text] [PDF]

				L. Hunyady and K. J. Catt Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970. [Abstract] [Full Text] [PDF]

				C. J. Boos and G. Y.H. Lip Prevention of Atrial Fibrillation by Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers J. Am. Coll. Cardiol., February 21, 2006; 47(4): 889 - 890. [Full Text] [PDF]

				J. Naukkarinen, M. Gentile, A. Soro-Paavonen, J. Saarela, H. A. Koistinen, P. Pajukanta, M.-R. Taskinen, and L. Peltonen USF1 and dyslipidemias: converging evidence for a functional intronic variant Hum. Mol. Genet., September 1, 2005; 14(17): 2595 - 2605. [Abstract] [Full Text] [PDF]

				S. Basu, A. Larsson, J. Vessby, B. Vessby, and C. Berne Type 1 Diabetes Is Associated With Increased Cyclooxygenase- and Cytokine-Mediated Inflammation Diabetes Care, June 1, 2005; 28(6): 1371 - 1375. [Abstract] [Full Text] [PDF]

				A. H. Berg and P. E. Scherer Adipose Tissue, Inflammation, and Cardiovascular Disease Circ. Res., May 13, 2005; 96(9): 939 - 949. [Abstract] [Full Text] [PDF]

				H. S. Lim, D. Felmeden, and G. Y.H. Lip Letter to the Editor: Angiotensin II-Mediated Vascular Inflammation: The Balance Between Vascular Endothelial Growth Factor and Angiopoietins Hypertension, February 1, 2005; 45(2): e3 - e3. [Full Text] [PDF]

				R. Morishita Is Vascular Endothelial Growth Factor a Missing Link Between Hypertension and Inflammation? Hypertension, September 1, 2004; 44(3): 253 - 254. [Full Text] [PDF]